EP2448564A2 - Solubility enhancing pharmaceutical formulation - Google Patents

Solubility enhancing pharmaceutical formulation

Info

Publication number
EP2448564A2
EP2448564A2 EP10763477A EP10763477A EP2448564A2 EP 2448564 A2 EP2448564 A2 EP 2448564A2 EP 10763477 A EP10763477 A EP 10763477A EP 10763477 A EP10763477 A EP 10763477A EP 2448564 A2 EP2448564 A2 EP 2448564A2
Authority
EP
European Patent Office
Prior art keywords
pharmaceutically acceptable
pharmaceutical composition
weight
acceptable salt
ezetimibe
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP10763477A
Other languages
German (de)
French (fr)
Inventor
Bilgic Mahmut
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bilgic Mahmut
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP2448564A2 publication Critical patent/EP2448564A2/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer

Definitions

  • the present invention relates to the pharmaceutical formulations comprising a therapeutically active substance with solubility problem in combination with other therapeutically active substances, and the methods for the preparation thereof, and the use thereof.
  • the present invention provides a combination effective in reducing elevated total cholesterol (total-C), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (Apo B) 5 and triglyceride (TG) levels, and in increasing high-density lipoprotein cholesterol (HDL-C) levels in patients with mixed hyperlipidemia or primary hypercholesterolemia (heterozygous familial and non-familial hypercholesterolemia); in reducing elevated total-C and LDL-C levels in patients with homozygous familial hypercholesterolemia (HoFH); and in reducing elevated sitosterol and campesterol levels in patients with homozygous familial sitosterolemia.
  • This effect provided by the combination of the present invention is hereinafter referred as "the desired effect”.
  • the mentioned combination comprises ezetimibe as a cholesterol absorption inhibitor and atorvastatin as an HMG-CoA reductase inhibitor.
  • Ezetimibe is a cholesterol absorption inhibitor with the chemical name of (3R,4S) -1- (4- fluorophenyl) -3- [(35)-3-(4-fluorophenyl)-3-hydroxypropyl] -4- (4-hydroxyphenyl) -2- azetidinone (Formula I).
  • Ezetimibe is disclosed for the first time in the U.S. patent application of 5631365 A (USRE37721E, US5767115 A, US5846966 A, WO9508532 Al and EP0720599 B1 are also members of the same patent family).
  • Processes for preparation of ezetimibe, pharmaceutical compositions comprising ezetimibe and the use of ezetimibe as a hypocholesterolemic agent are also disclosed in the same prior art.
  • ezetimibe in combination with HMG-CoA reductase inhibitors, such as lovastatin, pravastatin, fluvastatin, simvastatin and atorvastatin, is effective in reducing the plasma cholesterol levels and in the treatment of atherosclerosis.
  • HMG-CoA reductase inhibitors such as lovastatin, pravastatin, fluvastatin, simvastatin and atorvastatin
  • Ezetimibe is an anti-hyperlipidemic medication suitable for oral administration. It lowers serum cholesterol concentration by selectively inhibiting the absorption of phytosterols, such as cholesterol and the like, in the intestine. Its mechanism of action is complementary to that of HMG-CoA reductase inhibitors. Therefore, the cholesterol lowering effect of coadministered ezetimibe and HMG-CoA reductase inhibitors increases synergistically.
  • Atorvastatin is an HMG-CoA reductase inhibitor with a chemical name of ( ⁇ R, ⁇ R)-2-(4- Fluoro-phenyl)- ⁇ , ⁇ -dihydroxy-5-(l -methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-lH ' - pyrrole-1-heptanoic acid (Formula II).
  • Atorvastatin is disclosed for the first time in the patent numbered EP409281 Bl (EP1061073 Bl and US5273995 A are in the same patent family). Processes for preparing atorvastatin and the use of atorvastatin as a cholesterol biosynthesis inhibitor are also disclosed in the same prior art. f
  • Atorvastatin is a hypolipidemic drug which is a selective competitive inhibitor of 3-hydroxy- 3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase. Atorvastatin is the only drug in this class that can reduce both elevated LDL cholesterol and triglycerides in patients with hypercholesterolemia.
  • HMG-CoA 3-hydroxy- 3-methyl-glutaryl-coenzyme A
  • Ezetimibe a first-in-class, novel cholesterol absorption inhibitor.
  • the present invention based on the synergistic cholesterol lowering effect of ezetimibe and HMG-CoA reductase inhibitors is directed to obtain a combination of ezetimibe as an effective hypocholesterolemic agent with atorvastatin as a potent hypolipidemic agent that provides the desired effect.
  • the object of the invention is to provide a formulation of the invention comprising pharmaceutically acceptable, non-toxic and therapeutically effective amount of a combination of ezetimibe and atorvastatin in a dosage form such as a tablet designed to achieve the desired effect.
  • particle size reduction might not be always effective in increasing the dissolution rate of a drug, because as the particles get bigger during the manufacturing process of the pharmaceutical dosage form, increase in the particle size results in the agglomeration of particles.
  • nanoparticulate technology Another technique applied to increase the surface area is nanoparticulate technology.
  • problems are faced during the nanoparticulate formation, such as technical and mechanical limitations that prevent the reduction of particle size to nanoparticulate measures, and stability issues of these small sized active agent particles.
  • first pharmacological moiety is selected from HMG-CoA reductase inhibitors and second pharmacological moiety is selected from the group of active agents including cholesterol absorption inhibitors such as ezetimibe.
  • HMG-CoA reductase inhibitors are defined as atorvastatin, pravastatin, simvastatin, lovastatin, fluvastatin, cerivastatin and rosuvastatin.
  • HMG-CoA reductase inhibitors are defined to be atorvastatin, simvastatin and rosuvastatin.
  • TMs invention provides examples of formulations with known excipients. However, the solubility problem of ezetimibe is not mentioned here, hence no solution for this problem was presented by this application.
  • a method for treating or preventing sitosterolemia comprising administering at least one sterol absorption inhibitor (ezetimibe), optionally in combination with at least one lipid lowering agent, is disclosed in the International Patent Application with publication number 2002/058696.
  • Lipid lowering agent is defined to be an HMG-CoA reductase inhibitor selected from atorvastatin, pravastatin, simvastatin, lovastatin, fluvastatin, pitavastatin and rosuvastatin.
  • This invention particularly relates to the medical use of ezetimibe.
  • the solubility problem of ezetimibe is not mentioned here, hence no solution for this problem was presented by this application.
  • the present invention relates to a process for the preparation of a pharmaceutical composition
  • a pharmaceutical composition comprising therapeutically effective amount of ezetimibe or a pharmaceutically acceptable salt thereof and a therapeutically effective amount of atorvastatin or a pharmaceutically acceptable salt thereof for use in the manufacture of a medicament for the treatment of primary hypercholesterolemia (heterozygous familial and non-familial hypercholesterolemia), mixed hyperlipidemia, homozygous familial hypercholesterolemia and homozygous familial sitosterolemia, characterized in that ezetimibe or a pharmaceutically acceptable salt thereof and atorvastatin or a pharmaceutically acceptable salt thereof are preformulated in a series of manufacturing process steps.
  • primary hypercholesterolemia heterozygous familial and non-familial hypercholesterolemia
  • mixed hyperlipidemia homozygous familial hypercholesterolemia and homozygous familial sitosterolemia
  • the manufacturing process of the present invention which provides a formulation so as to obtain the desired effect is as follows: atorvastatin or a pharmaceutically acceptable salt thereof, at least one pharmaceutically acceptable diluent and optionally other pharmaceutically acceptable excipients, preferably a disintegrant and a glidant, are mixed and afterwards sieved to obtain the first mixture;
  • Ezetimibe or a pharmaceutically acceptable salt is dissolved in 1-propanol, 2- propanol, acetone or a mixture of these to obtain a granulation solution;
  • a pharmaceutically acceptable diluent is granulated by spraying the granulation solution
  • the granules obtained in the previous step are dried and sieved, and optionally mixed with other pharmaceutically acceptable excipients, preferably a disintegrant, to obtain the first mixture;
  • both of the mixtures are mixed to obtain a homogenous tablet, and the final mixture is optionally mixed with other pharmaceutically acceptable excipients, preferably a lubricant, and is finalized for tablet press;
  • both of the mixtures are fed separately to the tablet press machine to obtain a layered tablet;
  • tablets obtained in the previous step are film-coated.
  • the present invention based on the synergistic cholesterol lowering effect of ezetimibe and HMG-CoA reductase inhibitors is directed to obtain a combination of ezetimibe and atorvastatin to provide the desired effect.
  • a solubility problem is encountered in these attempts.
  • compositions comprising ezetimibe (or a pharmaceutically acceptable salt) and atorvastatin (or a pharmaceutically acceptable salt), which are preformulated in a series of manufacturing steps, show the optimum efficiency in the treatment of various cardiovascular diseases.
  • compositions comprising specific amounts of ezetimibe (or a pharmaceutically acceptable salt) and atorvastatin (or a pharmaceutically acceptable salt) and at least one diluent in an high amount and, optionally, at least one pharmaceutically acceptable excipient selected from the group of binders, disintegrants, lubricants and glidants, show the optimum efficiency in the treatment of various cardiovascular diseases.
  • atorvastatin or a pharmaceutically acceptable salt thereof, at least one pharmaceutically acceptable diluent and optionally other pharmaceutically acceptable excipients, preferably a disintegrant and a glidant, were mixed and afterwards sieved to obtain the first mixture;
  • ezetimibe or a pharmaceutically acceptable salt was dissolved in a granulation solution comprising 1-propanol, 2-propanol, acetone or a mixture of these.
  • ezetimibe usually tends to agglomerate
  • the granules obtained by spraying the granulation solution comprising ezetimibe onto a pharmaceutically acceptable diluent and after being dried and sieved exhibited a dissolution rate greater than 90% in the first 10 minutes in the dissolution medium of ezetimibe.
  • the second mixture was obtained by optionally mixing these granules with other pharmaceutically acceptable excipients, preferably a disintegrant.
  • Both of the mixtures were mixed together and this final mixture was optionally mixed with other pharmaceutically acceptable excipients, preferably a lubricant, and was finalized for tablet press or to obtain a layered tablet both of the mixtures were fed separately to the tablet press machine.
  • other pharmaceutically acceptable excipients preferably a lubricant
  • tablets obtained in the previous step were optionally film-coated.
  • variable cardiovascular diseases refers to primary hypercholesterolemia (heterozygous familial and non-familial hypercholesterolemia), mixed hyperlipidemia, homozygous familial hypercholesterolemia and homozygous familial sitosterolemia.
  • ezetimibe or a pharmaceutically acceptable salt thereof
  • atorvastatin or a pharmaceutically acceptable salt thereof
  • at least one pharmaceutically acceptable diluent in an amount of at least 60% by weight, preferably at least 70%, more preferably at least 80% by weight and if needed at least one pharmaceutically acceptable excipient selected from excipients such as binders, disintegrants, lubricants and glidants, which all of them are preferred to obtain the desired effect.
  • “Pharmaceutically acceptable salt of atorvastatin” may be derived from inorganic bases selected from the group of alkali metals such as sodium, lithium and potassium, earth alkali metals such as calcium and magnesium, and other inorganic bases such as aluminium, zinc, ammonium or organic bases selected from the group of arginine, betaine, caffeine, .
  • choline N,N'-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2- dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N- ethylpiperidine, glucamine, glucosamine, histidine, isopropylamine, lysine, methylglucosamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purine, theobromine, basic ion-exchange resins such as triethylamine, trimethylamine, tripropylamine, cyclic amines, substituted amines, primary, secondary, tertiary amines, and preferably calcium salt.
  • the pharmaceutically acceptable diluents may be selected from the group of lactose, microcrystalline cellulose, starch, pregelatinized starch, modified starch, calcium phosphate (dibasic and/or tribasic), calcium sulfate trihydrate, calcium sulfate dihydrate, calcium carbonate, kaolin, lactilol, powder cellulose, dextrose, dextrates, dextrin, sucrose, maltose, fructose, mannitol, sorbitol, xylitol, and the like.
  • the pharmaceutical composition of the invention comprises preferably lactose as diluent.
  • Lactose may be selected from the different forms of lactose such as lactose DC, lactose monohydrate, lactose anhydrous, and the like. Besides the lactose another diluent selected from the group listed above can also be added to the composition.
  • the pharmaceutically acceptable binders can be selected from the group of starch (e.g. potato starch, cornstarch or wheat starch), sucrose, glucose, dextrose, lactose, sugars like maltodexrin, natural and synthetic gums (e.g. acacia tree), gelatin, cellulose derivatives (e.g. microcrystalline cellulose, HPC, HEC, HPMC 5 carboxymethylcellulose, methylcellulose, ethylcellulose), polyvinylpyrrolidone, polyethylene glycol, waxes, calcium carbonate, calcium phosphate, alcohols (e.g. sorbitol, xylitol and mannitol) and water.
  • the binder is present in the formulation preferably in a range of 0-10% by weight, more preferably in a range of 0.1-5% by weight.
  • the pharmaceutically acceptable disintegrants may be selected from the group of starch (e.g. potato starch, corn starch), sodium starch glycolate, pregelatinized starch, cellulose derivatives (e.g. croscarmellose sodium, microcrystalline cellulose), polyvinylpyrrolidone, crospovidone, alginic acid, sodium alginate, clays (e.g. xanthan gum or Veegum), ion- exchange resins, effervescent systems such as those utilizing food acids and alkaline carbonate components, and the like.
  • croscarmellose sodium is used.
  • Disintegrant is present in the formulation preferably in a range of 0-10% by weight, more preferably in a range of 1-5% by weight.
  • the pharmaceutically acceptable glidants can be selected from the group of silicon dioxide, magnesium trisilicate, powdered cellulose, starch, talc, tribasic calcium phosphate, metallic stearates, calcium silicate and metallic lauryl sulfate.
  • silicon dioxide is used.
  • the weight % of the glidant in the formulation is lower than 1%.
  • the pharmaceutically acceptable lubricants can be selected from the group of metallic stearates (e.g. magnesium stearate, calcium stearate, aluminum stearate), fatty acid esters (e.g. sodium stearyl fumarate), fatty acids (e.g. stearic acid), fatty alcohols, glyceryl behenate, mineral oils, paraffins, hydrogenated vegetable oils, leucine, polyethylene glycols (PEG), metallic lauryl sulfates (e.g. sodium lauryl sulfate, magnesium lauryl sulfate), sodium chloride, sodium benzoate, sodium acetate and talk.
  • metallic stearates e.g. magnesium stearate, calcium stearate, aluminum stearate
  • fatty acid esters e.g. sodium stearyl fumarate
  • fatty acids e.g. stearic acid
  • fatty alcohols e.g. glyceryl behenate
  • mineral oils
  • Lubricant is present in the formulation preferably in a range of 0-10% by weight, more preferably in a range of 0.25-5% by weight.
  • antioxidants, protectors, stabilizers, solubility enhancers, electrolytes, sweeteners, colorants, coating agents can be used as other pharmaceutically acceptable excipients in the formulation.

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to the pharmaceutical formulations comprising a therapeutically active substance with solubility problem in combination with other therapeutically active substances, and the methods for the preparation thereof, and the use thereof.

Description

SOLUBILITY ENHANCING
PHARMACEUTICAL FORMULATION
Field of the invention
The present invention relates to the pharmaceutical formulations comprising a therapeutically active substance with solubility problem in combination with other therapeutically active substances, and the methods for the preparation thereof, and the use thereof.
Background of Invention
The present invention provides a combination effective in reducing elevated total cholesterol (total-C), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (Apo B)5 and triglyceride (TG) levels, and in increasing high-density lipoprotein cholesterol (HDL-C) levels in patients with mixed hyperlipidemia or primary hypercholesterolemia (heterozygous familial and non-familial hypercholesterolemia); in reducing elevated total-C and LDL-C levels in patients with homozygous familial hypercholesterolemia (HoFH); and in reducing elevated sitosterol and campesterol levels in patients with homozygous familial sitosterolemia. This effect provided by the combination of the present invention is hereinafter referred as "the desired effect". The mentioned combination comprises ezetimibe as a cholesterol absorption inhibitor and atorvastatin as an HMG-CoA reductase inhibitor.
Ezetimibe is a cholesterol absorption inhibitor with the chemical name of (3R,4S) -1- (4- fluorophenyl) -3- [(35)-3-(4-fluorophenyl)-3-hydroxypropyl] -4- (4-hydroxyphenyl) -2- azetidinone (Formula I).
Formula (I)
Ezetimibe is disclosed for the first time in the U.S. patent application of 5631365 A (USRE37721E, US5767115 A, US5846966 A, WO9508532 Al and EP0720599 B1 are also members of the same patent family). Processes for preparation of ezetimibe, pharmaceutical compositions comprising ezetimibe and the use of ezetimibe as a hypocholesterolemic agent are also disclosed in the same prior art. It is also disclosed that use of ezetimibe in combination with HMG-CoA reductase inhibitors, such as lovastatin, pravastatin, fluvastatin, simvastatin and atorvastatin, is effective in reducing the plasma cholesterol levels and in the treatment of atherosclerosis.
Ezetimibe is an anti-hyperlipidemic medication suitable for oral administration. It lowers serum cholesterol concentration by selectively inhibiting the absorption of phytosterols, such as cholesterol and the like, in the intestine. Its mechanism of action is complementary to that of HMG-CoA reductase inhibitors. Therefore, the cholesterol lowering effect of coadministered ezetimibe and HMG-CoA reductase inhibitors increases synergistically.
Atorvastatin is an HMG-CoA reductase inhibitor with a chemical name of (βR, δR)-2-(4- Fluoro-phenyl)- β,δ -dihydroxy-5-(l -methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-lH'- pyrrole-1-heptanoic acid (Formula II).
Formula (II)
Atorvastatin is disclosed for the first time in the patent numbered EP409281 Bl (EP1061073 Bl and US5273995 A are in the same patent family). Processes for preparing atorvastatin and the use of atorvastatin as a cholesterol biosynthesis inhibitor are also disclosed in the same prior art.f
Atorvastatin is a hypolipidemic drug which is a selective competitive inhibitor of 3-hydroxy- 3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase. Atorvastatin is the only drug in this class that can reduce both elevated LDL cholesterol and triglycerides in patients with hypercholesterolemia.
The synergistic cholesterol lowering effect of ezetimibe and HMG-CoA reductase inhibitors has been proved by various clinical trials:
• Davis HR, PuIa KK, Alton KB, Burner RE & Watkins RW. The Synergistic Hypocholesterolemic Activity of the Potent Cholesterol Absorption Inhibitor, Ezetimibe, in Combination With 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors in Dogs. Metabolism 2001; 50(10):1234-1241
• Sudhop T, Von Bergmann K. Cholesterol absorption inhibitors for the treatment of hypercholesterolaemia. Drugs 2002; 62(16):2333-47
• Gagne C, MD; Gaudet D, MD PhD; Bruckert E, MD PhD. Efficacy and Safety of
Ezetimibe Coadministered With Atorvastatin or Simvastatin in Patients With Homozygous Familial Hypercholesterolemia. Circulation 2002; 105; 2469-2475
• Davidson M.H., Ballantyne CM., Kerzner B., Melani L., Sager P.T., Lipka L., Strony J., Suresh R., Veltri E., For Ezetimibe Study Group. Efficacy and safety of ezetimibe coadministered with statins: randomised, placebo-controlled, blinded experience in
2382 patients with primary hypercholesterolemia. Journal of Clinical Practice, August 2004, 58(8): 746-755
• Gagne C; Bays H.E.; Weiss S.R.; Mata P.; Quinto K.; Melino M.; Cho M.; Musliner T.A.; Gumbiner B.I; Ezetimibe Study Group. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia.
Am J Cardiol 2002; 90: 1084-1091
• Christie M. Ballantyne, John Houri, Alberto Notarbartolo, Lorenzo Melani, Leslie J.
Lipka, Ramachandran Suresh, Steven Sun, Alexandre P. LeBeaut, Philip T. Sager ve Enrico P. Veltri. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial.
Circulation 2003; 107; 2490-2415
• Lipka L.J.. Ezetimibe: a first-in-class, novel cholesterol absorption inhibitor.
Cardiovascular Drug Reviews, 21(4); 293-312
• Kosoglu T, Meyer I, Veltri EP, et al. Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin. Br J Clin
Pharmacol. 2002
The present invention based on the synergistic cholesterol lowering effect of ezetimibe and HMG-CoA reductase inhibitors is directed to obtain a combination of ezetimibe as an effective hypocholesterolemic agent with atorvastatin as a potent hypolipidemic agent that provides the desired effect.
The object of the invention is to provide a formulation of the invention comprising pharmaceutically acceptable, non-toxic and therapeutically effective amount of a combination of ezetimibe and atorvastatin in a dosage form such as a tablet designed to achieve the desired effect.
Usually, when solid dosage forms such as tablets are administered orally, the drug must first dissolve in gastrointestinal fluids before exhibiting its effect. However dissolution problems arise with active agents such as ezetimibe with small particulate sizes. Low dissolution rates of these active agents affect their bioavailability adversely.
One of the known techniques applied to overcome the solubility problem of poorly soluble drugs is particle size reduction. Since the dissolution rate depends on the surface area of the particle directly, decreasing the size of the particles increases the total surface area, hence the dissolution rate.
However, particle size reduction might not be always effective in increasing the dissolution rate of a drug, because as the particles get bigger during the manufacturing process of the pharmaceutical dosage form, increase in the particle size results in the agglomeration of particles.
Another technique applied to increase the surface area is nanoparticulate technology. However some problems are faced during the nanoparticulate formation, such as technical and mechanical limitations that prevent the reduction of particle size to nanoparticulate measures, and stability issues of these small sized active agent particles.
Thus, there is a need for novel methods to overcome the solubility problem arisen from the combination of ezetimibe with other therapeutical agents, such as HMG-CoA reductase, which combination results in a synergistic effect.
In the International Patent Application with publication number WO 2006/110882, compounds comprising a first pharmacological moiety covalently connected to a second pharmacological moiety through a physiologically labile linker are described. First pharmacological moiety is selected from HMG-CoA reductase inhibitors and second pharmacological moiety is selected from the group of active agents including cholesterol absorption inhibitors such as ezetimibe. HMG-CoA reductase inhibitors are defined as atorvastatin, pravastatin, simvastatin, lovastatin, fluvastatin, cerivastatin and rosuvastatin. The mechanism of action of ezetimibe and HMG-CoA reductase inhibitors are indicated as complementary in this patent application. It is also stated that this synergistic effect has been proven by clinical trials. So, this invention relates to novel compounds consisting of two pharmacological moieties and the use thereof. The solubility problem of ezetimibe is not mentioned here, hence no solution for this problem was presented by this application. Stable antihyperlipoproteinemic oral pharmaceutical formulations which comprise ezetimibe, an HMG-CoA reductase inhibitor, disintegrants and glidants are disclosed in the International Patent Application with publication number 2006/134604. HMG-CoA reductase inhibitors are defined to be atorvastatin, simvastatin and rosuvastatin. TMs invention provides examples of formulations with known excipients. However, the solubility problem of ezetimibe is not mentioned here, hence no solution for this problem was presented by this application.
A method for treating or preventing sitosterolemia comprising administering at least one sterol absorption inhibitor (ezetimibe), optionally in combination with at least one lipid lowering agent, is disclosed in the International Patent Application with publication number 2002/058696. Lipid lowering agent is defined to be an HMG-CoA reductase inhibitor selected from atorvastatin, pravastatin, simvastatin, lovastatin, fluvastatin, pitavastatin and rosuvastatin. This invention particularly relates to the medical use of ezetimibe. The solubility problem of ezetimibe is not mentioned here, hence no solution for this problem was presented by this application.
The above-mentioned patent applications are directed to the combination of ezetimibe and HMG-CoA reductase inhibitors because of their synergistic effect. However, the solubility problem that inhibits efficient work on this combination is not mentioned in these patents or patent applications. So, there is still need for various solutions which would allow formulators to combine ezetimibe and HMG-CoA reductase inhibitors to achieve the desired effect.
Summary of the Invention
The present invention relates to a process for the preparation of a pharmaceutical composition comprising therapeutically effective amount of ezetimibe or a pharmaceutically acceptable salt thereof and a therapeutically effective amount of atorvastatin or a pharmaceutically acceptable salt thereof for use in the manufacture of a medicament for the treatment of primary hypercholesterolemia (heterozygous familial and non-familial hypercholesterolemia), mixed hyperlipidemia, homozygous familial hypercholesterolemia and homozygous familial sitosterolemia, characterized in that ezetimibe or a pharmaceutically acceptable salt thereof and atorvastatin or a pharmaceutically acceptable salt thereof are preformulated in a series of manufacturing process steps.
The manufacturing process of the present invention, which provides a formulation so as to obtain the desired effect is as follows: atorvastatin or a pharmaceutically acceptable salt thereof, at least one pharmaceutically acceptable diluent and optionally other pharmaceutically acceptable excipients, preferably a disintegrant and a glidant, are mixed and afterwards sieved to obtain the first mixture;
- Ezetimibe or a pharmaceutically acceptable salt is dissolved in 1-propanol, 2- propanol, acetone or a mixture of these to obtain a granulation solution;
a pharmaceutically acceptable diluent is granulated by spraying the granulation solution;
- the granules obtained in the previous step are dried and sieved, and optionally mixed with other pharmaceutically acceptable excipients, preferably a disintegrant, to obtain the first mixture;
- optionally, both of the mixtures are mixed to obtain a homogenous tablet, and the final mixture is optionally mixed with other pharmaceutically acceptable excipients, preferably a lubricant, and is finalized for tablet press;
- optionally, both of the mixtures are fed separately to the tablet press machine to obtain a layered tablet;
optionally, tablets obtained in the previous step are film-coated.
Detailed Description of the Invention
The present invention based on the synergistic cholesterol lowering effect of ezetimibe and HMG-CoA reductase inhibitors is directed to obtain a combination of ezetimibe and atorvastatin to provide the desired effect. However, as mentioned before, a solubility problem is encountered in these attempts. To achieve the desired effect from the combination of ezetimibe and atorvastatin, there is the need to overcome the solubility problem of ezetimibe and to find the appropriate amounts of active agents and excipients of the composition.
Surprisingly, it was found that pharmaceutical compositions comprising ezetimibe (or a pharmaceutically acceptable salt) and atorvastatin (or a pharmaceutically acceptable salt), which are preformulated in a series of manufacturing steps, show the optimum efficiency in the treatment of various cardiovascular diseases.
As another embodiment of the invention, it was found that pharmaceutical compositions comprising specific amounts of ezetimibe (or a pharmaceutically acceptable salt) and atorvastatin (or a pharmaceutically acceptable salt) and at least one diluent in an high amount and, optionally, at least one pharmaceutically acceptable excipient selected from the group of binders, disintegrants, lubricants and glidants, show the optimum efficiency in the treatment of various cardiovascular diseases.
The problem of solubility has been solved by applying a series of manufacturing steps to ezetimibe and atorvastatin according to their solubility characteristics.
- atorvastatin or a pharmaceutically acceptable salt thereof, at least one pharmaceutically acceptable diluent and optionally other pharmaceutically acceptable excipients, preferably a disintegrant and a glidant, were mixed and afterwards sieved to obtain the first mixture;
- Then, ezetimibe or a pharmaceutically acceptable salt was dissolved in a granulation solution comprising 1-propanol, 2-propanol, acetone or a mixture of these. Although ezetimibe usually tends to agglomerate, the granules obtained by spraying the granulation solution comprising ezetimibe onto a pharmaceutically acceptable diluent and after being dried and sieved, exhibited a dissolution rate greater than 90% in the first 10 minutes in the dissolution medium of ezetimibe. The second mixture was obtained by optionally mixing these granules with other pharmaceutically acceptable excipients, preferably a disintegrant.
Both of the mixtures were mixed together and this final mixture was optionally mixed with other pharmaceutically acceptable excipients, preferably a lubricant, and was finalized for tablet press or to obtain a layered tablet both of the mixtures were fed separately to the tablet press machine.
Finally, tablets obtained in the previous step were optionally film-coated.
The term "various cardiovascular diseases" as used herein refers to primary hypercholesterolemia (heterozygous familial and non-familial hypercholesterolemia), mixed hyperlipidemia, homozygous familial hypercholesterolemia and homozygous familial sitosterolemia.
The terms "in a specific amount", "in an high amount" and "optionally" as used herein refer to ezetimibe (or a pharmaceutically acceptable salt thereof) in an amount of 0.1 to 20% by weight, atorvastatin (or a pharmaceutically acceptable salt thereof) in an amount of 1 to 40% by weight, at least one pharmaceutically acceptable diluent in an amount of at least 60% by weight, preferably at least 70%, more preferably at least 80% by weight and if needed at least one pharmaceutically acceptable excipient selected from excipients such as binders, disintegrants, lubricants and glidants, which all of them are preferred to obtain the desired effect.
"Pharmaceutically acceptable salt of atorvastatin" may be derived from inorganic bases selected from the group of alkali metals such as sodium, lithium and potassium, earth alkali metals such as calcium and magnesium, and other inorganic bases such as aluminium, zinc, ammonium or organic bases selected from the group of arginine, betaine, caffeine, . choline, N,N'-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2- dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N- ethylpiperidine, glucamine, glucosamine, histidine, isopropylamine, lysine, methylglucosamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purine, theobromine, basic ion-exchange resins such as triethylamine, trimethylamine, tripropylamine, cyclic amines, substituted amines, primary, secondary, tertiary amines, and preferably calcium salt.
The pharmaceutically acceptable diluents may be selected from the group of lactose, microcrystalline cellulose, starch, pregelatinized starch, modified starch, calcium phosphate (dibasic and/or tribasic), calcium sulfate trihydrate, calcium sulfate dihydrate, calcium carbonate, kaolin, lactilol, powder cellulose, dextrose, dextrates, dextrin, sucrose, maltose, fructose, mannitol, sorbitol, xylitol, and the like. The pharmaceutical composition of the invention comprises preferably lactose as diluent. Lactose may be selected from the different forms of lactose such as lactose DC, lactose monohydrate, lactose anhydrous, and the like. Besides the lactose another diluent selected from the group listed above can also be added to the composition.
The pharmaceutically acceptable binders can be selected from the group of starch (e.g. potato starch, cornstarch or wheat starch), sucrose, glucose, dextrose, lactose, sugars like maltodexrin, natural and synthetic gums (e.g. acacia tree), gelatin, cellulose derivatives (e.g. microcrystalline cellulose, HPC, HEC, HPMC5 carboxymethylcellulose, methylcellulose, ethylcellulose), polyvinylpyrrolidone, polyethylene glycol, waxes, calcium carbonate, calcium phosphate, alcohols (e.g. sorbitol, xylitol and mannitol) and water. The binder is present in the formulation preferably in a range of 0-10% by weight, more preferably in a range of 0.1-5% by weight.
The pharmaceutically acceptable disintegrants may be selected from the group of starch (e.g. potato starch, corn starch), sodium starch glycolate, pregelatinized starch, cellulose derivatives (e.g. croscarmellose sodium, microcrystalline cellulose), polyvinylpyrrolidone, crospovidone, alginic acid, sodium alginate, clays (e.g. xanthan gum or Veegum), ion- exchange resins, effervescent systems such as those utilizing food acids and alkaline carbonate components, and the like. Preferably croscarmellose sodium is used. Disintegrant is present in the formulation preferably in a range of 0-10% by weight, more preferably in a range of 1-5% by weight.
The pharmaceutically acceptable glidants can be selected from the group of silicon dioxide, magnesium trisilicate, powdered cellulose, starch, talc, tribasic calcium phosphate, metallic stearates, calcium silicate and metallic lauryl sulfate. Preferably silicon dioxide is used. The weight % of the glidant in the formulation is lower than 1%.
The pharmaceutically acceptable lubricants can be selected from the group of metallic stearates (e.g. magnesium stearate, calcium stearate, aluminum stearate), fatty acid esters (e.g. sodium stearyl fumarate), fatty acids (e.g. stearic acid), fatty alcohols, glyceryl behenate, mineral oils, paraffins, hydrogenated vegetable oils, leucine, polyethylene glycols (PEG), metallic lauryl sulfates (e.g. sodium lauryl sulfate, magnesium lauryl sulfate), sodium chloride, sodium benzoate, sodium acetate and talk. Lubricant is present in the formulation preferably in a range of 0-10% by weight, more preferably in a range of 0.25-5% by weight. In addition, antioxidants, protectors, stabilizers, solubility enhancers, electrolytes, sweeteners, colorants, coating agents can be used as other pharmaceutically acceptable excipients in the formulation.
The formulation examples of the invention are given below. These examples are given only to explain the invention and the scope of the invention is not limited to these examples.
EXAMPLES
Example 1.
* Equivalent of 10 mg of atorvastatin
Example 2.
* Equivalent of 20 mg of atorvastatin Example 3.
* Equivalent of 40 mg of atorvastatin
Example 4.
* Equivalent of 80 mg of atorvastatin

Claims

CLAIMS A process for the preparation of a pharmaceutical composition comprising therapeutically effective amount of ezetimibe or a pharmaceutically acceptable salt thereof and a therapeutically effective amount of atorvastatin or a pharmaceutically acceptable salt thereof for use in the manufacture of a medicament for the treatment of primary hypercholesterolemia (heterozygous familial and non-familial hypercholesterolemia), mixed hyperlipidemia, homozygous familial hypercholesterolemia and homozygous familial sitosterolemia, characterized in that ezetimibe or a pharmaceutically acceptable salt thereof and atorvastatin or a pharmaceutically acceptable salt thereof are preformulated in a series of manufacturing process steps.
1. The process according to claim 1, characterized in that atorvastatin or a pharmaceutically acceptable salt thereof, at least one pharmaceutically acceptable diluent and optionally other pharmaceutically acceptable excipients, preferably a disintegrant and a glidant, are mixed and afterwards sieved to obtain the first mixture.
2. The process according to claim 1, characterized in that ezetimibe or a pharmaceutically acceptable salt is dissolved in solution comprising 1-propanol, 2- propanol, acetone or a mixture of these to obtain a granulation solution; granulation is achieved by spraying the granulation solution onto a pharmaceutically acceptable diluent and after the granules are dried and sieved, they are optionally mixed with other pharmaceutically acceptable excipients, preferably a disintegrant, to obtain the second mixture.
3. The process according to claim 1, characterized in that both of the mixtures are optionally mixed together and this final mixture is optionally mixed with other pharmaceutically acceptable excipients, preferably a lubricant, and finalized for tablet press or to obtain a layered tablet optionally both of the mixtures are fed separately to the tablet press machine.
4. The pharmaceutical composition prepared according to any one of the claims between 1 and 4, characterized in that the pharmaceutical composition comprises, based on the weight of the core tablet, - ezetimibe or a pharmaceutically acceptable salt thereof in an amount of 0.1 to
20% by weight,
- atorvastatin a pharmaceutically acceptable salt thereof in an amount of 1 to 40% by weight,
- at least one pharmaceutically acceptable excipient selected from excipients such as binders, disintegrants, diluents, lubricants and glidants.
5. The pharmaceutical composition prepared according to any one of the claims between 1 and 4, characterized in that the pharmaceutical composition comprises, based on the weight of the core tablet, - ezetimibe or a pharmaceutically acceptable salt thereof in an amount of 0.1 to
20% by weight,
- rosuvastatin a pharmaceutically acceptable salt thereof in an amount of 1 to
40% by weight,
at least one pharmaceutically acceptable diluent in an amount of at least 60% by weight, preferably at least 70%, more preferably at least 80% by weight, and,
at least one pharmaceutically acceptable excipient selected from excipients such as binders, disintegrants, diluents, lubricants and glidants.
6. The pharmaceutical composition prepared according to any one of the claims between
1 and 4, characterized in that the pharmaceutical composition comprises atorvastatin calcium as the pharmaceutically acceptable salt.
7. The pharmaceutical composition prepared according to any one of the claims between 1 and 4, characterized in that the pharmaceutical composition comprises a diluent, preferably lactose.
8. The pharmaceutical composition prepared according to any one of the claims between
1 and 4, characterized in that the pharmaceutical composition comprises a disintegrant, preferably croscarmellose sodium.
9. The pharmaceutical composition according to claim 9 characterized in that the disintegrant is present in the formulation preferably in a range of 0-10% by weight, more preferably in a range of 1-5% by weight.
10. The pharmaceutical composition prepared according to any one of the claims between 1 and 4, characterized in that the pharmaceutical composition comprises a glidant, preferably silicon dioxide.
11. The pharmaceutical composition according to claim 11 characterized in that the weight % of the glidant in the formulation is lower than 1%.
12. The pharmaceutical composition prepared according to any one of the claims between
1 and 4, characterized in that the pharmaceutical composition preferably comprises a lubricant, preferably magnesium stearate.
13. The pharmaceutical composition according to claim 13 characterized in that the lubricant is present in the formulation preferably in a range of 0-10% by weight, more preferably in a range of 0.25-5% by weight.
14. The pharmaceutical composition according to any one of the previous claims, characterized in that the pharmaceutical composition is in solid dosage form for oral administration.
15. The pharmaceutical composition according to claim 15, characterized in that the solid dosage form is a tablet, preferably a film tablet.
EP10763477A 2009-07-02 2010-06-25 Solubility enhancing pharmaceutical formulation Withdrawn EP2448564A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR200905149 2009-07-02
PCT/TR2010/000123 WO2011002422A2 (en) 2009-07-02 2010-06-25 Solubility enhancing pharmaceutical formulation

Publications (1)

Publication Number Publication Date
EP2448564A2 true EP2448564A2 (en) 2012-05-09

Family

ID=43411648

Family Applications (1)

Application Number Title Priority Date Filing Date
EP10763477A Withdrawn EP2448564A2 (en) 2009-07-02 2010-06-25 Solubility enhancing pharmaceutical formulation

Country Status (2)

Country Link
EP (1) EP2448564A2 (en)
WO (1) WO2011002422A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2013006332A (en) * 2013-06-05 2014-12-19 Alparis Sa De Cv Oral pharmaceutical compositions for use in dyslipidemias.
CN103340852A (en) * 2013-07-01 2013-10-09 北京阜康仁生物制药科技有限公司 Pharmaceutical composition containing ezetimibe and atorvastatin
CN103784436B (en) * 2014-02-27 2016-06-01 安徽联创生物医药股份有限公司 A kind of blood fat-decreasing compound preparation and its preparation method
CN104013617A (en) * 2014-05-13 2014-09-03 万特制药(海南)有限公司 Composition containing ezetimibe and atorvastatin calcium and preparation method of composition
TR201702101A2 (en) * 2017-02-13 2018-08-27 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi ATORVASTATIN CALCIUM AND EZETIMIBIN PHARMACEUTICAL TWO-LAYER TABLET COMPOSITION
TR201820324A2 (en) * 2018-12-25 2020-07-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi ATORVASTATIN CALCIUM AND EZETİMİBİN PHARMACEUTICAL DOUBLE LAYER TABLET FORMULATION
KR102496243B1 (en) * 2020-01-14 2023-02-07 일동제약(주) A tablet comprising atorvastatin and ezetimibe
WO2022023206A1 (en) 2020-07-27 2022-02-03 Krka, D.D., Novo Mesto Bilayer tablet comprising ezetimibe and atorvastatin

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI94339C (en) 1989-07-21 1995-08-25 Warner Lambert Co Process for the preparation of pharmaceutically acceptable [R- (R *, R *)] - 2- (4-fluorophenyl) -, - dihydroxy-5- (1-methylethyl) -3-phenyl-4 - [(phenylamino) carbonyl] -1H- for the preparation of pyrrole-1-heptanoic acid and its pharmaceutically acceptable salts
US5631365A (en) 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
PL205343B1 (en) 2001-01-26 2010-04-30 Schering Corp The use of substituted azetidinone compounds for the treatment of sitosterolemia
AR040588A1 (en) * 2002-07-26 2005-04-13 Schering Corp PHARMACEUTICAL FORMULATION INCLUDING AN INHIBITOR OF CHOLESTEROL ABSORPTION AND AN INHIBITOR OF A HMGCO TO REDUCTASE
US20070112050A1 (en) 2005-04-12 2007-05-17 Psivida Inc. HMGCoA reductase inhibitor combinations and uses thereof
WO2006134604A1 (en) * 2005-06-15 2006-12-21 Hetero Drugs Limited Combination composition of cholesterol absorption inhibitor and 3-hydroxy-3-methylglutaryl-coenzyme a (hmg-coa) reductase inhibitor
EP1741427A1 (en) * 2005-07-06 2007-01-10 KRKA, D.D., Novo Mesto Pharmaceutical composition comprising simvastatin and ezetimibe
EP2120882A2 (en) * 2007-02-23 2009-11-25 Krka Pharmaceutical composition containing a cholesterol absorption inhibitor
WO2009024889A2 (en) * 2007-08-21 2009-02-26 Ranbaxy Laboratories Limited Pharmaceutical composition comprising a hmg-coa reductase inhibitor and ezetimibe
TR200806300A2 (en) * 2008-08-22 2010-03-22 B�Lg�� Mahmut Solubility enhancing pharmaceutical formulation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2011002422A2 *

Also Published As

Publication number Publication date
WO2011002422A3 (en) 2011-04-28
WO2011002422A2 (en) 2011-01-06

Similar Documents

Publication Publication Date Title
EP2448919A2 (en) Solubility and stability enchancing pharmaceutical formulation
EP2448564A2 (en) Solubility enhancing pharmaceutical formulation
AU2010201739B2 (en) A stable pharmaceutical composition comprising a fixed dose combination of fenofibrate and an HMG-CoA reductase inhibitor
CN103800279B (en) atorvastatin calcium composition
WO2009024889A2 (en) Pharmaceutical composition comprising a hmg-coa reductase inhibitor and ezetimibe
WO2006134604A1 (en) Combination composition of cholesterol absorption inhibitor and 3-hydroxy-3-methylglutaryl-coenzyme a (hmg-coa) reductase inhibitor
EP2328563B1 (en) Solubility enhancing pharmaceutical formulation
US20100204195A1 (en) Pharmaceutical Compositions and Process for Making Them
US9095515B2 (en) Ezetimibe compositions
US20070014846A1 (en) Pharmaceutical compositions comprising fenofibrate and atorvastatin
US20070116756A1 (en) Stable pharmaceutical compositions
WO2008068217A2 (en) Pharmaceutical composition comprising a coated hmg-coa reductase inhibitor and an inhibitor of the renin-angiotensin system
JP5722034B2 (en) Stable pharmaceutical composition comprising one or more HMG-CoA reductase inhibitors
EP2566465A2 (en) Stable rosuvastatin formulations
WO2008075320A2 (en) Antilipidemic pharmaceutical compositions and process for preparation thereof
CN101115478A (en) A stable pharmaceutical composition comprising a fixed dose combination of fenofibrate and an HMG-CoA reductase inhibitor
CA2730665C (en) Dosage form containing a statin
EP1651194B1 (en) Stable controlled release pharmaceutical compositions containing fenofibrate and pravastatin
ES2387913T3 (en) Combination preparations of salts of O-acetylsalicylic acid
EP4188338A1 (en) Bilayer tablet comprising ezetimibe and atorvastatin
WO2010021609A1 (en) Solubility and stability enhancing pharmaceutical formulation
WO2011002424A2 (en) Solubility and stability enchancing pharmaceutical formulation
WO2020139237A2 (en) A bilayer tablet formulation of atorvastatin calcium and ezetimibe
US20090233898A1 (en) Pharmaceutical Compositions Comprising Simvastatin and Ezetimibe
WO2012002921A1 (en) Multiple dosage forms comprising fenofibrate or fenofibric acid in combination with hmg co a reductase inhibitors such as statins

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20120126

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BILGIC, MAHMUT

RIN1 Information on inventor provided before grant (corrected)

Inventor name: BILGIC, MAHMUT

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20150923

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20170103